June 6, 2017
Novo Nordisk to sell its haemophilia B drug in EU
European Commission has granted marketing authorisation for Novo Nordisk’s Refixia for the treatment of adolescents and adults with haemophilia B.
Pharmaceuticals, Biotechnology and Life Sciences
European Commission has granted marketing authorisation for Novo Nordisk’s Refixia for the treatment of adolescents and adults with haemophilia B.